Introduction {#s1}
============

RIG-I (Retinoic acid-inducible gene I) encoded by the DDX58 gene in the human genome ([@B1], [@B2]) and MDA5 (Melanoma Differentiation-Associated protein 5) encoded by the IFIH1 gene ([@B3], [@B4]) are known as important protein initiators of earliest immune responses to viral infection. A relatively large body of work has focused on understanding their roles in triggering the same innate immune pathway as they indeed share many similarities at a structural and functional level. However, it is becoming increasingly clear that there are unique differences between RIG-I and MDA5, such as their activation mechanisms and contextual functionalities, that need to be considered in order to fully appreciate their individual function. A comprehensive analysis of multiple aspects of RIG-I and MDA5 from their evolutionary origins and behavior among different species to their structures and molecular signaling will allow for a more nuanced understanding of their functional purposes.

Functional Similarities and Differences Between RIG-I and MDA5 {#s2}
==============================================================

The innate immune response is a combination of non-specific defense mechanisms by the host that are critical for early detection and inhibition of pathogen growth before the adaptive immune response has time to produce proper cell-mediated immunity, such as the development of antibodies and cytotoxic T-lymphocyte responses (CTL) against the invading pathogen and/or the pathogen-infected cells ([@B5]). Cells of the innate immune arm, such as leukocytes and epithelial cells, are able recognize general components of the microbes (e.g., viruses) that are shared among related microbes. These microbial structures are called pathogen-associated molecular patterns (PAMPs) (e.g., viral dsRNA) that are specifically recognized by the cellular pattern recognition receptors (PRRs) (e.g., RIG-I, MDA5, or Toll-like receptors TLRs) which are then activated ([Figure 1](#F1){ref-type="fig"}). The specific signaling mechanisms of RIG-I and MDA5 activation will be discussed in detail below. Here, the cascade of event leading to IFN1 production is briefly summarized. Upon binding to PAMP (e.g., dsRNA), the activated RIG-I and MDA5 interact with the mitochondrial antiviral signaling proteins (MAVS), which forms a multilayered protein complex contain several different proteins ([@B6]--[@B9]). The MAVS complex then catalyzes the interaction of inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) and the serine/threonine-protein kinase 1 (TBK1) ([@B10]--[@B12]), which phosphorylate the transcription factors interferon regulatory factors 3 and 7 (IRF3 and IRF7) ([@B13]). Phosphorylated p-IRF7 ([@B14]) and -pIRF3 ([@B15]) factors then dimerize and translocate into the nucleus, where they activate the expression of the type 1 interferon genes (IFN1: IFNα and IFNβ). IFN1 proteins are then exported out of the cell to activate IFN1 signaling cascade by binding to their receptor (the IFNα/β receptor or IFNAR) either on the same cells or neighboring cells in an autocrine or paracrine fashion. This results in the production of more IFN1 (in a positive feedback loop) and a variety of interferon-stimulated genes (ISGs), which mediate vasodilation near the site of the pathogen infection and uptake of fluid, recruitment of innate immune cells, such as macrophages, neutrophils, and dendritic cells to the site of the infection that is aided by chemokine gradients to mediate innate immune cell-mediated killing of the infected cells ([@B16]).

![RIG-I/MDA5 signaling pathway RIG-I and MDA5 are first activated by recognition of PAMP dsRNA, which causes them to interact with MAVS. Following the activation of MAVS by RIG-I/MDA5, a molecular cascade involves the interaction of IKKε and TBK1, which is followed by phosphorylation of the transcription factors IRF3 and IRF7, ensure to translocate the phosphorylated p-IRF3 and p-IRF7 into the nucleus, where they dimerize and bind to transcription factor binding sites of the IFNα and IFNβ genes to activate their transcriptions. Expression and exportation of these genes into the cellular milieu trigger the IFN1 signaling cascade in an autocrine or paracrine fashion to induce expression of hundreds of interferon stimulated genes (ISGs) and inflammatory genes to confer antiviral resistance. RIG-I and MDA5 also activate the NF-κB pathway. RIG-I appears to act upstream of the canonical pathway, which results in the translocation of the two functional NF-κB units (p50 and p65) into the nucleus, while MDA5 appears to affect NF-κB expression independently from this pathway. Figure created using BioRender software.](fimmu-10-01586-g0001){#F1}

RIG-I and MDA5 appear to differentially induce IFN1 in response to different viral pathogens ([@B17]), with RIG-I generally responding most potently to negative-strand RNA viruses, such as influenza viruses ([@B18], [@B19]), bunyaviruses ([@B20], [@B21]), filoviruses ([@B22]), and rhabdoviruses ([@B18], [@B23]) as well as the positive-stranded Japanese encephalitis virus ([@B18]), while MDA5 is activated during infection by positive-strand picornaviruses ([@B18], [@B24], [@B25]) and arteriviruses ([@B26], [@B27]) as well as by hepatitis D virus ([@B28]), Kaposi\'s sarcoma-associated herpesvirus (KSHV) ([@B29]). RIG-I and MDA5 may also play a role in recognizing non-viral pathogens, as MDA5 has been found to respond to malaria ([@B30]) ([Figure 2](#F2){ref-type="fig"}). Neither are individually critical in reovirus ([@B24]) and in dengue virus infection ([@B24], [@B31]) but the presence of either in combination with Toll-like receptor 3 (TLR3) is critical to have effective anti-viral repsonses ([@B32]). Each serves an additive role during West Nile virus infection ([@B33]), which is likely mediated by the production of multiple PAMP species in the infected cells ([@B34]). Indeed, RIG-I and MDA5 have also been shown to recognize different sections of the same viral genome due to their differing preferences for RNA binding ([@B35]), illustrating how RIG-I and MDA5 can act both independently and synergistically. This has also been shown functionally in viruses where both RIG-I and MDA5 have been found to be essential to induce the necessary levels of IFNβ signaling for antiviral control against paramyxovirus ([@B18], [@B36]--[@B38]) and rotavirus infections ([@B39]).

![Venn diagram comparing the signaling and functional similarities and differences between RIG-I and MDA5.](fimmu-10-01586-g0002){#F2}

While RIG-I and MDA5 participate in the IFN1 signaling pathway ([@B40]), it is clear from animal modeling that they might be functionally distinct. While C57BL/6 MDA5 KO mice exhibit no obvious phenotypes ([@B18]), C57BL/6 RIG-I KO have high embryonic lethality as they don\'t live past 3 weeks of birth and experience growth retardation and liver degeneration ([@B18], [@B41]). Furthermore, when RIG-I KO mice are back crossed onto the more genetically flexible 129S1 strain ([@B18]), these mice can spontaneously develop colitis symptoms ([@B42]). Clinical cases with mutations in RIG-I and MDA5 have distinct autoimmune presentations, with RIG-I mutations being associated with atypical Singleton-Merten Syndrome, while MDA5 mutations have been linked to classical Singleton-Merten Syndrome, Aicardi-Goutières syndrome, Systemic Lupus Erythematosus, Type 1 Diabetes and Graves disease ([@B43], [@B44]) ([Figure 2](#F2){ref-type="fig"}). There is growing evidence that overt innate-immune interferon signaling plays a critical role in the development of other forms of autoimmune conditions ([@B45]). Taken together, this suggests that RIG-I and MDA5 may differ significantly in their roles during development as well as in responding to different types of viral infection that is partially dependent on the PAMPs that are available in any given context.

There is also increasing evidence that RIG-I and MDA5 have additional distinct molecular functionalities in immune signaling ([@B43]). It is well-established that the interferon regulatory factor (IRF) and innate immune NFκB cytokine signaling pathways have many areas of cross-regulation and expression ([@B46]). Accordingly, both RIG-I and MDA5 have been shown to activate NFκB signaling during RSV infection, but only RIG-I appears to act upstream of the canonical IκBα-NFκB pathway ([@B47], [@B48]) ([Figure 1](#F1){ref-type="fig"}). While both are known to activate NFκB mediated expression of IL-6 and pro-IL-1β through the interaction of CARD9 with BCL10 ([@B49], [@B50]), the independence of MDA5 from the IκBα pathway suggests that it influences NFκB signaling in other as yet uncharacterized ways ([@B43]). A possible explanation for MDA5\'s independence from the IκBα pathway may be that MDA5-mediated NFκB (but not IRF) signaling requires TRIM25, which activates RIG-I by ubiquitination (to be discussed in detail below). This potentially implicates TRIM25 in other mechanisms besides activating RIG-I ([@B51], [@B52]). RIG-I (but not MDA5) also induces inflammasome assembly-mediated cleavage and maturation of pro- IL-1β by caspase 1 ([@B24], [@B34], [@B53]). Finally, RIG-I has been shown to inhibit RNAi complexes mediated by the endoribonuclease Dicer, which is encoded by the DICER1 gene and cleaves dsRNA and pre-micro RNA into short single-stranded RNA fragments known as small interfering RNA (siRNA) and microRNA ([@B54]), by interacting with the probable ATP-dependent RNA helicase DHX58 (also known as the Laboratory of Genetics and Physiology 2 LGP2 protein), which inhibits Dicer ([@B55]) as well as the Dicer-complex protein TRBP ([@B56]). LGP2 has been shown to exhibit conflicting effects on RIG-I and MDA5 signaling ([@B57]--[@B59]), and future studies are needed in order to clarify these regulatory mechanisms.

Structures of RIG-I and MDA5 {#s3}
============================

RIG-I and MDA5 are expressed in all cell types ([@B60]), but are most well-known for their functions inside innate immune cells, such as macrophages, neutrophils, and dendritic cells, as well as in other cells like mucosal epithelial cells. They are classified as ATP-dependent DExD/H box RNA helicases. Their structure is highly helical and consists of two caspase activating and recruiting domains (CARD) at the N terminus of \~85 amino acids each, followed by a flexible hinge region and the helicase domain that consists of the RecA-like Hel1 and Hel2 domains with an ATP binding and hydrolyzing domain at their interface ([Figures 3A,B](#F3){ref-type="fig"}). In particular, the structure of the ATP binding site distinguishes RIG-I and MDA5 from other helicase proteins, such as Dicer. Unlike other DExD/H box helicases where RNA binding catalyzes the ATP binding site to become structurally organized, the ATP binding site in RIG-I and MDA5 remains comparatively open and structurally dynamic following RNA binding. This is aided by the ATP binding site being formed by an interface between the two Hel domains, which are relatively far apart ([@B64]).

![Organization and known structures of RIG-I and MDA5. **(A,B)** Graphic representing the domain organization of RIG-I **(A)** and MDA5 **(B)**. **(C--E)** Known structures of human RIG-I and MDA5, with X-ray crystallography structures of RIG-I Hel-CTD **(C)** and MDA5-Hel-CTD **(D)** interacting with dsRNA, and CARD1/2 of RIG-I interacting with the MAVS CARD domain **(E)**. In **(C--E)**, the helicase domains are shown in red, the CTD in purple, RNA in green, the CARD1 domain in blue, the CARD2 domain in aquamarine and the MAVS CARD domain in orange **(C)** was adapted from reference ([@B61]), **(D)** from reference ([@B62]), and **(E)** from reference ([@B63]).](fimmu-10-01586-g0003){#F3}

These structural features are connected by another flexible hinge region to the unique and predominantly β-sheet C terminal domain (CTD), which recognizes and binds to RNA ([@B65]). The CTD in RIG-I and MDA5 contains a zinc binding domain that is related to those of the GDP/GTP exchange factors ([@B66]). Each protein also contains a positively charged groove within this domain that recognizes dsRNA and this groove is structurally unique in each protein, potentially explaining their different RNA binding preferences ([@B66]). RIG-I primarily recognizes short double-stranded RNA with 5′ triphosphate groups ([@B67]--[@B75]), while MDA5 primarily recognizes long double-stranded RNA ([@B76]--[@B79]) (to be discussed in detail below.) It is notable in this regard that the Hel-CTD motifs adopt different orientations relative to dsRNA in RIG-I and MDA5. Specifically, the RIG-I Hel-CTD domain is tilted relative to dsRNA with the CTD interacting with the 5′ and 3′ ends of the dsRNA ([@B61]), whereas the MDA5 Hel-CTD domain runs parallel to the RNA strand ([Figures 3C,D](#F3){ref-type="fig"}).

Activation of RIG-I and MDA5 by Post-translational Modifications {#s4}
================================================================

The series of steps required for RIG-I and MDA5 activation have been described in depth elsewhere ([@B80]--[@B84]). Briefly summarized, these proteins endogenously exist in the cytoplasm of the cell in a phosphorylated and inactivated conformation when they are not activated by PAMP (dsRNA) ([@B85]--[@B87]) ([Figures 4A,F](#F4){ref-type="fig"}). Phosphorylation is mediated at the N terminal CARD domains (S8 and T170) of RIG-I by PKC-α/β ([@B88], [@B89]) and at the C terminal RNA interaction domain (S854, S855, and T770) by CKβ ([@B90]). On the other hand, MDA5 is phosphorylated at S828 by RIOK3 ([@B91]) as well as by other yet unknown kinases ([@B92], [@B93]). RIG-I is also acetylated at K909 in its C terminal domain that requires deacetylation by HDAC6 to be able to recognize RNA in its activated form ([@B94]). Upon recognition of PAMP (dsRNA), RIG-I unfolds into an open and activated state that is mediated by the flexible hinge regions between the CARD domains and the helicase domain, and between the helicase and the C terminal domain ([@B64], [@B87], [@B95]--[@B98]) ([Figure 4B](#F4){ref-type="fig"}). On the contrary, there is evidence to suggest that MDA5 has a more dynamic structure ([@B99]). Unlike a model of RIG-I activation described above, MDA5 exists in a conformational equilibrium between close and open forms, with close forms favored in the dsRNA unliganded state. While not yet formally demonstrated, it is possible that MDA5 may be inhibited in the absence of the dsRNA ligand by its structural dynamics, which may prevent strong protein-protein interactions ([Figure 4F](#F4){ref-type="fig"}). However, upon binding to dsRNA ligand, MDA5 adopts an open and activated form, which is perhaps more conducive for protein-protein interactions ([Figures 4G,H](#F4){ref-type="fig"}).

![Activation mechanisms of RIG-I and MDA5. RIG-I and MDA5 are activated by interacting with viral dsRNA at the C terminal domain. In their endogenous and inactivated state, RIG-I and MDA5 are phosphorylated at their N and C terminal domains **(A,F)**. MDA5 may exist between open and close forms in its inactivated state **(F)**. Upon recognizing PAMP dsRNA, the C terminal domain becomes dephosphorylated and ubiquitinated for RIG-I and dephosphorylated for MDA5 **(B,G)**. RIG-I also dimerizes **(B)**. Next, RIG-I oligomerizes **(D)** and MDA5 forms longer filaments on dsRNA **(H)**, and the N terminal CARD domains of RIG-I becomes dephosphorylated **(C)** then ubiquitinated **(D)**. Finally, the CARD domain of the RIG-I oligomers interacts with the mitochondrial protein MAVS **(E)**, and the MDA5 dsRNA filaments also activate MDA5 (though it has a weaker CARD-CARD interaction with MAVS) **(I)**. Figure created using BioRender software.](fimmu-10-01586-g0004){#F4}

Once the C terminal domains have been de-phosphorylated, the E3 ubiquitin ligase Riplet attaches ubiquitin peptides onto the C terminal domain of RIG-I at residues K849 and K851 ([@B100], [@B101]). It was previously shown that ubiquitination by Riplet was necessary for opening RIG-I and for ubiquitination of the CARD domain ([@B102]). However, *in-situ* studies found that dsRNA was sufficient to weaken the interaction between purified RIG-I C terminal domain and RIG-I CARD domains ([@B86]) and that dsRNA was necessary for Riplet ubiquitination ([@B103]), calling into question the sequential order for RIG-I activation ([Figure 4C](#F4){ref-type="fig"}). Following de-phosphorylation of the CARD domain by the phosphatase PP1-α/γ ([@B92]), this domain is polyubiquinated at K172 by the E3 TRIM25 ubiquitin ligase ([@B104]), which itself is activated by Caspase 12 ([@B105]) ([Figure 4D](#F4){ref-type="fig"}). TRIM25 interacting with RIG-I may also be mediated by their mutual interactions with certain host long non-coding RNA (lncRNA), which occurs outside of the dsRNA recognizing domain in the CTD of RIG-I ([@B106]).

A recent study showed that Riplet rather than TRIM25 was primarily responsible for ubiquitinating and activating RIG-I ([@B103]). However, there are several factors to take into consideration with this study. These recent results were obtained using KO 293T and mouse embryonic fibroblast (MEF) cells and that it was not clear whether K63 ubiquitination occurred at other known lysine sites in RIG-I. The question remains whether Riplet can ubiquitinate other lysine residues in the absence of TRIM25. Additionally, *in-situ* experiments comparing RIG-I ubiquitination by Riplet and TRIM25 utilized an E2 enzyme ([@B103]) that had been found to be specific for Riplet ([@B107]). While the E2 that utilizes TRIM25 has not yet been identified, TRIM25 has been shown to ubiquitinate RIG-I *in-situ* when a general mixture of E2 proteins was used ([@B108]). The protein levels of TRIM25 may also have to be at a certain level in order for it to productively ubiquitinate RIG-I, as the ubiquitin protease USP15 deubiquitinates TRIM25 at later time points in viral infection ([@B109]).

Finally, TRIM25 has been found to be essential for RIG-I activation and IFN signaling *in-vitro* and *in-vivo*. For the former, siRNA-mediated knock-down ([@B110], [@B111]), cellular knock-out ([@B112]) and inhibition by viral protein ([@B109], [@B113]--[@B116]) conditions for TRIM25 in multiple cell types have been shown to change RIG-I cellular localization ([@B110]) and to negatively affect RIG-I K63 ubiquitination, association with MAVS and IFN signaling \[when the constitutively active RIG-I CARD domain was overexpressed ([@B109], [@B112]--[@B116]) or during viral infection ([@B109], [@B111], [@B114])\]. Viral inhibition of TRIM25 may even be a source of a positive selection during the evolution of certain viruses, as NS1 IAV proteins have been found to interact with species specific TRIM25 ([@B114]). For the latter, MEFs from TRIM25 KO mice have significantly downregulated IFN1 production upon viral infection ([@B113]) and KO mice for NLRP12, which is a competitive interactor with TRIM25 to RIG-I, show increased interferon production and more resistance to viral infection ([@B117]). The known contributions of TRIM25 to innate immunity have recently been summarized elsewhere ([@B52]).

It is clear that both Riplet and TRIM25 can mediate K63-linked polyubiquitination. However, it has also been found that *in-situ* incubation of purified RIG-I CARD domains with ubiquitin can be activated by free and unlinked K63 polyubiquitin chains ([@B118]), calling into question whether TRIM25 only attaches K63-linked ubiquitin motifs to RIG-I-CARD or if it also catalyzes the formation of unlinked K63 polyubiquitination chains ([@B119]). A possible explanation for these differing results is that RIG-I has been shown to be covalently K63 ubiquitinated by TRIM25 when analyzed by mass spectrometry from cells ([@B104]), while experiments that demonstrate non-covalent K63 ubiquitination are those involve primarily interactions with purified proteins.

It has also been recently found that RIG-I is K63 ubiquitinated at K164 and that it may be functionally redundant to K172 ([@B120], [@B121]), with their ubiquitination possibly upregulating the K63 ubiquitination of the other 6 lysine residues in RIG-I ([@B121]). However, it is unknown whether TRIM25 ubiquitinates K164 or any of the other RIG-I lysine residues. Notably, these additional lysine residues in the CARD and C terminal domains of RIG-I and MDA5 are known to be K27 and K48 ubiquitinated \[which are associated with degradation of RIG-I ([@B122], [@B123]) and MDA5 ([@B123])\], but the four listed above appear to be the essential residues for activation of RIG-I ([@B122], [@B124]).

The presence of K63 ubiquitin modifications on MDA5 is more controversial. Independent studies have found that MDA5 is ([@B125], [@B126]) or is not ([@B126]) K63 polyubiquitinated. It has also been independently found that TRIM25 does not affect ubiquitination of MDA5 (without distinguishing between K63 and K48 polyubiquitination) ([@B104]) and for TRIM25 to increase K63 ubiquitination ([@B125]), the only apparent difference in the experimental models being the usage of HEK293T ([@B104], [@B126]) vs. HEK293 ([@B125]) cells. TRIM65 has also been recently found to be essential for MDA5 activation by K63 polyubiquitination at K743 ([@B127]). It is clear that additional studies are needed in order to clarify the ubiquitination mechanisms of MDA5.

Oligomerization and Filamentation to Activate RIG-I and MDA5 Functions {#s5}
======================================================================

Upon binding to PAMP (dsRNA), RIG-I oligomerizes with other RIG-I/dsRNA complexes to form helical oligomers ([@B128]) in a 2:2 complex using the purified RIG-I protein ([@B87]), where the activating ubiquitin motifs serve as a scaffold to link the oligomers together ([@B118]). These oligomers have been found to be necessary under normal conditions to activate RIG-I. This may be due to the helical structure of the RIG-I oligomers closely matching those formed by MAVS ([@B63]), which is known to form filaments *in-vitro* ([@B129], [@B130]) mediated by its own CARD domains ([@B131], [@B132]). A structural model of MAVS activation by RIG-I has been proposed of stacking MAVS CARD domains on top of RIG-I CARD domains to extend the RIG-I helix ([@B133]).

The minimum length of dsRNA found to activate RIG-I is 13 base pairs, which is equivalent to the minimum length to facilitate the formation of a 2-RIG-I/dsRNA dimer ([@B75]). That being said, shorter (\~10 bp) 5′ppp stem loop dsRNA complexes that have previously been used to obtain X-ray crystallographic structures of RIG-I interacting with dsRNA ([@B61], [@B134], [@B135]) ([Figure 3C](#F3){ref-type="fig"}) can also activate IFNβ signaling in cells ([@B135], [@B136]) and in mice ([@B136]). Furthermore, A549 cells that were transfected with RIG-I plasmid 6 h prior to RNA transfection had a minimum dsRNA length of only 8--10 bp required for activation ([@B75]). This indicates that RIG-I oligomerization may not be necessary for activation of the IFNβ pathway under some experimental conditions, which need to be further investigated.

MDA5 has also been shown to oligomerize to form long RNA-associated filaments *in vitro* ([@B62], [@B137], [@B138]) ([Figures 3D](#F3){ref-type="fig"}, [4H](#F4){ref-type="fig"}), which may be aided by chaperone proteins ([@B139]). Given that the K743 residue found to have been ubiquitinated by TRIM65 ([@B127]) is located on the surface of Hel2, it is possible that K63 ubiquitin residues may also help stabilize MDA5-dsRNA filaments ([@B140]). However, MDA5 also spontaneously forms filaments and induce MAVS to form filaments independently of ubiquitin *in-situ*. It is also thought that the formation of longer filaments by MDA5 may be mediated by a longer linkage region between CARD2 and Hel1 than in RIG-I by 50 amino acids (the length of which is well-conserved across species), allowing for the association of more CARD domains in an oligomer ([@B133]).

The formation of longer filaments by RIG-I has been more controversial, giving rise to two alternate models of RIG-I activation: formation of individual single unit of RIG-I with short dsRNA monomers (leaving a free dsRNA end, such as a hairpin loop), which then oligomerizes via CARD tetramerization that is linked by their ubiquitin chains, or filamentation on longer dsRNA. Like MDA5, RIG-I can form filaments *in-situ* independent of ubiquitin ([@B141], [@B142]) and induces MAVS to also form filaments ([@B142]), and MAVS is known to form filaments *in-vitro* ([@B129], [@B130]) mediated by its own CARD domains ([@B131], [@B132]). However, RIG-I filamentation on an RNA template (forming "beads on a string") as opposed to smaller-scale oligomerization hasn\'t yet been shown to occur *in-vitro*. Part of the reasons for the suggestion that RIG-I was strongly activated by shorter dsRNA was based the comparison on mass equivalents of RNA species as there were less 5′ triphosphorylated ends for longer dsRNAs with greater mass than shorter dsRNAs with more 5′ triphosphorylated ends ([@B76]). However, when RNA species were normalized by molar equivalence, dsRNA length appeared to be positively correlated with RIG-I signaling ([@B141]--[@B143]), which became insignificant at around 500 bp ([@B141], [@B143]). It is significantly shorter than the length of dsRNA that activates MDA5, which forms filaments on 2,000 bp dsRNA ([@B137]). The kinetics of RIG-I and MDA5 interacting with dsRNA (which will be discussed in detail below) might possibly explain the decrease in dsRNA length efficiency to activate RIG-I as compared to MDA5, as RIG-I seems to first recognize the 5′ppp end before sliding down the length of the dsRNA ([@B144]), whereas MDA5 dynamically associates and disassociates along the length of long dsRNA ([@B137]). Meanwhile, it is still unclear whether RIG-I can preferentially be activated by longer dsRNA independently of its unknown ability to form filaments *in-vitro* ([@B145]).

Modes of RLR-MAVS Interaction and RLR Downstream Signaling {#s6}
==========================================================

Once fully activated and oligomerized, the RIG-I CARD domain can then interact with MAVS ([@B146]--[@B149]) ([Figures 4E,I](#F4){ref-type="fig"}), which is part of a protein complex containing a variety of other cellular proteins ([@B6]--[@B9]). While the MDA5 CARD domain has much weaker direct association with MAVS than the RIG-I CARD domain, it is sufficient to lead to its activation and potentiates activation of MAVS by RIG-I ([@B146]), the mechanisms of which have yet to be determined. The activated MAVS complex then initiates a molecular cascade which eventually results in expression of IFN1 ([@B150]) ([Figure 2](#F2){ref-type="fig"}).

Interestingly, full length RIG-I, when overexpressed, has been found to associate with MAVS in the absence of activating dsRNA and the interaction can be ablated by phosphorylation at S8 and T170 ([@B87]), suggesting that the CARD phosphorylation sites function at least in part to prevent association of the inactive form of RIG-I with MAVS. Furthermore, the crystal structure of the interaction between the RIG-I CARD and MAVS CARD domains shows the RIG-I CARD2 domain (92--173) interacting with MAVS CARD domains on the outside of the tetramer and the RIG-I CARD1 (1--87) domain facing toward the center of the tetramer ([@B63]) ([Figure 3E](#F3){ref-type="fig"}). NMR solution structures of RIG-I CARD2 also shows that T170 (which is required for dephosphorylation by PP1-α/γ) is largely buried within the CARD2 domain in a section that would be in closer contact with the helicase domains, suggesting that dephosphorylation of T170 affects an interaction domain between CARD2 and the C terminus ([@B151]). Furthermore, NMR of a C terminal construct of RIG-I with the CARD2 domain shows stable interactions of CARD2 and the C terminal domain ([@B151]). What all this may mean is that, while the CARD1 domain of RIG-I is somewhat exposed in its inactivated form and therefore can be shown to interact with MAVS, full exposure and engagement of both RIG-I CARD domains (CARD1 and CARD2) with the CARD domain of MAVS is necessary in order to induce IFN1 signaling. The CARD domains of RIG-I also appear to be generally structurally stable, as electron microscopic structures have been obtained of the full length RIG-I bound to blunt-ended dsRNA showing both CARD domains exposed ([@B87]). On the contrary, the CARD domains of MDA5 may be comparatively more flexible than those of RIG-I in order to mediate long MDA5-dsRNA filament formation ([@B99]).

The activated MAVS complex induces association of the inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKKε) and the serine/threonine-protein kinase 1 (TBK1) ([@B10]--[@B12]), which collectively phosphorylate the interferon regulatory factors 3 and 7 (IRF3 and IRF7) ([@B13]) ([Figure 1](#F1){ref-type="fig"}). IKKε and TBK1 also interact with a number of other co-factors ([@B152], [@B153]), such as the DEAD-box helicase 3 (DDX3) ([@B154]). The activated p-IRF3 ([@B15]) and p-IRF7 ([@B14]) then translocate into the nucleus and dimerize, where they then act as the primary transcription factors for IFNα and IFNβ, respectively. Existing evidence suggests that IFNα is more primarily produced in the earliest time points following RIG-I/MDA5 activation, while IFNβ is produced later and is responsible for more robust anti-viral control throughout the innate immune response period ([@B155]). There is also a distinction between innate immune cell types for IFN1 production, as cells like fibroblasts and conventional dendritic cells produce IFNα and IFNβ ([@B41], [@B156]), while neutrophils only produce IFNβ ([@B157]) and plasmacytoid dendritic cells only produce IFNα primarily through the TLR signaling pathways ([@B41], [@B158]). Signaling through RIG-I is also known to be essential for the process of TLR-mediated phagocytosis by macrophages ([@B159]).

Interferons are then secreted out of the cell, where they bind to their own receptor (IFNAR) and activate the Janus kinase/Signal Transducer and Activator of Transcription proteins (JAK/STAT) signaling pathways, which result in a positive feedback signaling loop to further increase RIG-I/MDA5 expression and activation ([@B160]) and IFN1 production ([@B161], [@B162]). Expression levels of RIG-I and MDA5 have consistently been found to be upregulated downstream of type I ([@B163], [@B164]) and type II ([@B165], [@B166]) IFN signals. MDA5 upregulation has additionally been found to occur independently of cytokine expression at least during picornavirus infection ([@B167]).

Specific RNA Features Recognized by RIG-I and MDA5 {#s7}
==================================================

One of the most obvious distinctions between RIG-I and MDA5 is in the RNA species to which they bind for activation ([Figures 1](#F1){ref-type="fig"}, [5](#F5){ref-type="fig"}). RIG-I has the highest affinity for short dsRNA that is tri-phosphorylated at the 5′ end ([@B67]--[@B75]), with RIG-I having been found to directly interact with the 5′ tri-phosphate group of the dsRNA ([@B71], [@B73]). While RIG-I can bind to ss-5′ tri-phosphorylated RNA ([@B69]), RIG-I cannot be activated by it ([@B69], [@B168], [@B169]), likely due to a conformational need to recognize double-stranded RNA. As a result, RIG-I is greatly attenuated by a 5′ overhang as well as those with a 3′ overhanging the 5′ tri-phosphate end ([@B170]). In fact, a single unpaired 5′ tri-phosphorylated nucleotide is sufficient to competitively inhibit RIG-I, which has been exploited by RNA viruses to evade RIG-I recognition and IFN1 signaling ([@B171]). The unique preference of RIG-I for 5′ tri-phosphorylated RNA can be explained by the specific orientation that the RIG-I C terminus adopts when directly interacting with the 5′ tri-phosphate group of the 5′ tri-phosphorylated dsRNA ([@B71], [@B73]) as compared to unphosphorylated blunt-ended dsRNA ([@B172]).

![RNA species that interact with RIG-I and MDA5. Table summarizes the general structural features of RNA species, their source during experimental studies and their ability to activate the ATPase functions of RIG-I and MDA5. RNA constructs are shown in green, and DNA constructs in purple.](fimmu-10-01586-g0005){#F5}

The minimally required and exclusionary features of the 5′ and 3′ dsRNA ends for RIG-I activation have proven to be complex. Certain studies suggest that a 5′ diphosphate group is the minimum feature required for RIG-I binding and activation, with 5′ monophosphate dsRNA failing to productively activate RIG-I as compared to 5′ di and tri-phosphate dsRNA ([@B173]). Additionally, RIG-I poorly distinguishes between dsRNAs with either 5′ tri-phosphate and 5′ diphosphate group. When the free energies of each interaction are calculated, the affinity for 5′ triphosphate being lowered by disassociation of magnesium from the RIG-I/dsRNA complex. Both are significantly more favorable for binding RIG-I monophosphate dsRNA ([@B174]). This similarity in affinity appears to be important in the context of infection with viruses that produce 5′ diphosphate RNAs, such as reoviruses ([@B173]). Likewise, the difference of energic binding between monophosphate dsRNA and bi- and tri-phosphate dsRNAs is likely important for distinction between self (host) and non-self (foreign) RNA, the mechanisms of which will be discussed in detail below. The ATP hydrolysis functions of RIG-I have been shown to drive rapid disassociation from certain RNA features, such as 5′ monophosphate dsRNA ([@B174], [@B175]) and 5′OH RNA ([@B144], [@B176]), which is particularly important for 5′ monophosphate dsRNA because it is found in mRNA after decapping during the mRNA degradation process ([@B177]).

On the other hand, other studies have shown that RIG-I can interact with monophosphate dsRNA to a certain degree, as has been found to be the case for short synthetic dsRNA with a 5′ and 3′ monophosphate group ([@B69]), poly(I:C) digested with RNase III ([@B76]) \[which generates 5′ mono-phosphate/3′-OH dsRNA ([@B178])\] and HCV RNA ([@B179]) and mitochondrial RNA \[in the p53 deficient mice ([@B180])\] digested with RNase L \[which produces 5′ OH and 3′ mono-phosphate dsRNA at subnanomolar levels ([@B181]), as has been found to be the case for HCV RNA ([@B179]).\] It appears that the 5′ monophosphate is the determinate feature for RIG-I activation independently of the 5′ or 3′ OH group in all these cases. A possible explanation for the discrepancy between the studies was that higher order RNA structures might compensate for the less optimal 5′ and 3′ ends, as monophosphate dsRNA that did not contain stem-loop structures did not activate RIG-I and RNA regions repetitive in certain nucleotides had been found to be critical for RIG-I activation ([@B179]). Future studies are required to further characterize the behavior of RIG-I with these RNA species.

As previously mentioned, MDA5 preferentially associates with long dsRNA ([@B76]--[@B79]). The crystal structure and molecular modeling of MDA5/dsRNA complex suggest that it can recognize the entire first turn of the blunt-ended dsRNA ([@B182]) in a similar way as LGP2 can ([@B183]). Like RIG-I and MDA5, LGP2 belongs to the ATP-dependent DExD/H box RNA helicases ([@B184]), which is structurally similar to RIG-I and MDA5 but lacks the CARD domains at the N terminus ([@B185]). MDA5 has also been found to be activated by the digested products of RNase L specifically from parainfluenza virus ([@B186]).

The presence of certain repetitive RNA elements appears to be another contributing factor in determining interaction of RNA with RIG-I and MDA5, which has recently been described in detail elsewhere ([@B187]). While RIG-I and MDA5 are mostly implicated in the immune response to RNA viruses, it has also been found to be activated by 5′ tri-phosphorylated dsRNA intermediates generated by cellular RNA polymerase III from AT-rich DNA sequences ([@B188]) and during infection with Epstein-Barr virus (a DNA virus) ([@B189]). RIG-I has additional binding preferences for certain nucleotide motifs, such as uridine-rich 5′ tri-phosphorylated hairpin RNA ([@B190]), synthetic AU- rich hairpins ([@B191]) and those naturally found in the genomes of Sendai virus defective-interfering (DI) particles ([@B192]), measles ([@B193]), Influenza A virus (IAV) ([@B194]) and in KSHV RNA transcripts ([@B195]), and poly (U/UC) regions ([@B196]) and poly (A/AG) regions ([@B197]) in the antisense Hepatitis C virus (HCV) genome. It is of particular interest that the poly (A/AG) HCV regions are located significantly downstream of the 5′triphosphate group ([@B197]), thus potentially implicating other parts of RIG-I (e.g., helicase domain) as potential RNA interacting domains. Repetitive RNA elements may also be important in allowing for interaction of inhibitory RNAs that do not have 5′ or 3′ features needed for full activation of RIG-I, as has been shown to be the case with GA-rich regions in circular long-non-coding RNA lnc-Lsm3b ([@B198]). These specific interactions explain their primary role as anti-viral receptors, as these viral motifs are mostly not found in cellular RNAs ([@B199]).

RIG-I and MDA5 have been particularly implicated in their response to RNA genomes of viral defective interfering (DI) particles, as these defective viral genomes (DVGs) have originally been found to induce interferon signaling ([@B150]). DI particles are produced by many viruses during infection, and while they are similar in many regards to standard viral particles, such as in appearance and composition, they cannot productively infect cells ([@B200]). This is largely thought to be due to the presence of large and deleterious deletions in the DVG of DI particles ([@B201]). Some DVG RNAs have also been noted to have "copy-back" motifs in which one end of the genome can base pair with an inverted copy at the opposite end of the genome, which may be due to stalled and aberrant replication ([@B202], [@B203]).

Copy-back RNA motifs specifically seem to be important for RLR activation in that they tend to contain hairpin motifs and 5′ tri-phosphate groups, as has been found for Sendai ([@B204]--[@B206]), measles ([@B35], [@B207]), and chikungunya ([@B35]) DVG RNAs in activating RIG-I. In the case of IAV, DVG RNAs might even be more potent activators of RIG-I than the full-length viral genome. Cells that were blocked from viral protein synthesis experienced RIG-I mediated IFN1 expression when infected with IAV stocks grown in chicken embryonic eggs (which produced higher relative quantities of DI particles with DVG RNAs) but not with IAV grown in cell culture, indicating that RIG-I activation by the genomes from primarily non-DI IAV particles may require active viral RNA synthesis ([@B208]). A potential explanation to this observation is that RIG-I appears to be activated by the full viral genome via its panhandle structure, the affinity of which is lowered by the presence of mismatched and unpaired nucleotides in this region of the viral genome that is conserved across influenza virus strains ([@B209]). However, the overall panhandle structure is conserved between DVGs ([@B205]) and the full length viral genome ([@B209]), and deletions within DVGs are monogenic and internal ([@B210]). The specific molecular mechanisms of enhanced RIG-I signaling by IAV DVGs have yet to be elucidated, although the level of exposure of the panhandle may play a role. While the full extent of MDA5 interacting with DI RNA is currently unknown, MDA5 appears to be more predominantly activated by DVG RNA than RIG-I specifically in dendritic cells early in the viral infection cycle ([@B211]), which may be a contributor toward the phenomenon of DI particles enhancing dendritic cell maturation ([@B212]).

The comparative abilities for DI particles vs. infectious virions to activate RIG-I and MDA5 have important implications for understanding viral pathogenesis and for vaccine development. There is a burgeoning interest in this regard, especially in populations which are typically more challenging to achieve successful preventative vaccination, such as elderly populations with IAV vaccination ([@B213]). Elderly populations in general do not develop as strong of memory immune responses to vaccines as their younger counterparts ([@B214]--[@B217]) and have been found to have decreased RIG-I mediated IFN1 signaling ([@B218]). Correspondingly, the influenza vaccine has been shown to decrease in effectiveness in older populations as the influenza season progresses ([@B219]). A DI-vaccine that strongly activates innate immune cells and increases the adaptive immune response could therefore potentially boost the immune responses to vaccines in more vulnerable populations. Additionally, DI particles have shown to be an important contributor of viral persistence ([@B200], [@B220], [@B221]). This raises the question of whether a viral infection may alternate between producing primarily infectious virions which eventually activates the innate immune response and producing primarily DI particles which requires less cellular activity but may initiate an even stronger innate immune response ([@B222]--[@B224]). Taken altogether, DI particles provide yet another layer of distinction between RIG-I and MDA5 in terms of how each recognizes different species of dsRNA.

Distinction of Self (Host) and Non-self (Foreign) RNAs by RIG-I and MDA5 {#s8}
========================================================================

The preference for specific RNA species by RIG-I and MDA5 allow for them to distinguish between viral RNA and host RNA in most circumstances ([@B225]), although the specific mechanisms of distinction are not as clear for MDA5 as for RIG-I. Studies from clinical cases of MDA5 mutations provide contradictory models, with certain mutations found in Aicardi-Goutières syndrome (AGS) increasing MDA5 avidity for self RNA ([@B226]) with Alu retroelements found to be significantly enriched for interaction with AGS MDA5 mutations ([@B227]). The modification of dsRNA by host cells may be a primary inhibitor of MDA5 activation by host RNA as knockout of adenosine deaminase (ADAR1), which weakens dsRNA structures, allows wild-type MDA5 to be activated by Alu retroelements ([@B227]). However, other MDA5 mutations decrease affinity for known MDA5 ligands and ATPase activity, yet still demonstrate increased IFNβ expression ([@B228], [@B229]).

For RIG-I, a highly conserved residue in the C-terminal RNA binding pocket (H830) has been found to sterically exclude canonical self-RNA by the means of the N~1~-2′O-methyl self-RNA motif, also known as Cap1 RNA ([@B61], [@B230]). This results in a low binding affinity of RIG-I to cellular Cap1 RNA and decreased ATPase activity as compared to PAMP (dsRNA) ([@B61], [@B231]). Flaviviruses take advantage of this precise discrimination by encoding a viral 2′-O-methyltransferase capable of N~1~-2′O-methylating its positive-strand RNA genome in order to evade RIG-I recognition and IFN1 activation ([@B230]). Conversely, the mutations E373A and C268F found in the RIG-I protein in patients with auto-immune disorder Singleton-Merten syndrome confer the ability of the protein to recognize Cap1 RNA and become activated by ATP dependent and independent mechanisms, respectively ([@B232]). Furthermore, the E373Q mutation of RIG-I, which was designed to constitutively bind ATP, was found to increase the affinity of RIG-I with ribosomal RNA ([@B233]). It is noteworthy that host RNA contains additional internal RNA modifications and non-Watson-Crick base pairing which can inhibit activation of the other known dsRNA-sensing protein, the interferon-induced double-stranded RNA-activated protein kinase (PKR) ([@B234]), and it is known that synthetic 5′ triphosphorylated RNA containing pseudouridine, 2-thiouridine or 2′-O-methylated uridine has significantly decreased ability to activate RIG-I ([@B67]), which has been demonstrated to occur by preventing RIG-I filament formation *in-situ* ([@B142]). N-6-methyladenosine (m6A) nucleotides, which are well-known nucleotide modifications among viruses ([@B235]), have also been found to ablate dsRNA binding to RIG-I ([@B236]).

It has been demonstrated that certain RNA-DNA hybrid constructs with ribonucleotides at positions 2 and 5 of the DNA strand can bind to RIG-I and activate its ATPase activity ([@B75]). ATPase activity is necessary for full activation of RIG-I and expression of IFNβ ([@B75], [@B237]), so the minimum requirement of a motif not found in host RNA for ATPase activity has significant implications for the distinction between self and non-self RNAs. Expanding on this observation, exogenous ATPase activity may also be sufficient to potentiate RIG-I and MDA5, as LGP2 ATPase mutant mice are significantly more susceptible to viral infection even in the presence of functional RIG-I and MDA5 ([@B238]). However, this model is further complicated by certain RNA-DNA hybrids that are able to bind RIG-I and activate ATPase activity, but don\'t induce IFNβ expression ([@B75]). It is currently undetermined whether such hybrids can sterically inhibit RIG-I due to the presence of mostly dNTPs or whether they inhibit RIG-I in a yet undescribed way.

Recent kinetic studies of RIG-I and MDA5 activation by PAMP (dsRNA) help illustrate how ATPase activity is critical for their function and distinction between host (self) and foreign (non-self) RNA. RIG-I binding to ATP is sufficient for interaction with dsRNA ([@B144], [@B176]). RIG-I ATPase activity is inhibited in the absence of PAMP (dsRNA) by a helical arm that blocks the ATPase site ([@B239]). Upon interaction with PAMP (dsRNA), the helical arm shifts and the two helicase domains are brought together to form an active ATPase site ([@B239]). RIG-I then catalyzes ATP to break the 5′ppp dsRNA interactions within seconds. ATP is then rapidly hydrolyzed to facilitate translocation of RIG-I to the opposite dsRNA end, after which the RIG-I oligomers can form ([@B144]). On the other hand, ATP hydrolysis drives rapid disassociation of RIG-I from host RNA features. These features include dsRNA with a 5′ monophosphate group ([@B174], [@B175]) that is found in mRNA after decapping during the mRNA degradation process ([@B177]) and 3′ overhang RNA ([@B144], [@B170]) found in miRNA ([@B240]) as well as other RNA motifs, such as 5′OH RNA ([@B144], [@B176]) found in bacteria ([@B241]). Furthermore, an impaired ATPase functionality increases the promiscuity of RIG-I binding these host RNA motifs ([@B144], [@B176], [@B242]).

Similar ATPase functions have been found during MDA5 filamentous formation. The C terminus of MDA5 is critical to form organized helical filaments ([@B138]) and ATP binding drives association and hydrolysis and disassociation from foreign dsRNA \[with little coordination being observed between neighboring MDA5 proteins ([@B137])\] in a manner that involves MDA5 twisting along its flexible and hydrophobic interface domains ([@B243]). Taken together, ATPase activity may be directed toward rapid disassociation from host dsRNA and degradation of RNA-DNA hybrids, but primarily act on the translocation pathway upon interaction with PAMP (dsRNA). It is also possible that host and hybrid dsRNAs could inactivate RIG-I independently of their ability to bind the C-terminus and activate ATPase activity. This has been shown, for example, for a hybrid RNA that has one strand consists mostly of DNA except at positions 2 and 5, which appears to bind RIG-I and activate its ATPase activity but doesn\'t activate IFN1 signaling ([@B75]). Future studies are needed in order to determine these differential interaction mechanisms.

Novel Mechanisms of Inhibition or Activation of RIG-I and MDA5 by Cellular RNAs {#s9}
===============================================================================

Contrary to the traditional paradigm, there is increasing evidence to suggest that RIG-I and MDA5 interact with certain host RNA motifs, resulting in auto-activation or auto-inhibition of the IRF pathway ([Figure 5](#F5){ref-type="fig"}). One of the most strongly supported models is activation by host and viral circular RNAs (circRNA). Originally found in a variety of pathogen genomes, circRNAs in eukaryotic cells were first thought to be byproducts of the pre-mRNA splicing process. However, they have later been found to be produced by a non-canonical "backsplicing" process and there is increasing evidence to suggest that they play some important regulatory roles ([@B244]), suggesting that they may have specifically evolved for this purpose. RIG-I was first found to interact with circRNA produced *in situ* ([@B245]). Interestingly, the minimum component required for RIG-I activation is an intron of pathogenic origin to be spliced out during the circularization process. As human introns have been found to be associated with many RNA binding proteins, it is speculated that these proteins may have prevented circularization of this particular synthetic circRNA used in this study ([@B245]) and that host RNA binding proteins normally prevent endogenous circRNAs from being detected by the innate immune system. Nevertheless, some viral infections can potentially expose these endogenous circRNAs for immune detection, as has recently been found to be the case for a novel host-derived circRNA (lnc-Lsm3b) that is IFN-inducible and shows a down-regulation of its binding to host proteins during viral infection and therefore appears to compete with viral dsRNA as an inhibitor of the RIG-I signaling feedback loop ([@B198]). Similar inhibitory mechanisms have also been noted for RNA products of the exonuclease SKIV2L ([@B246]). Finally, recent studies have found that hepatitis C virus (HCV) infection increases the expression of certain cellular RNAs that can inhibit RIG-I function. HCV infection increased the mRNA levels of hepatic selenoprotein, which was able to bind to RIG-I through a hairpin structure and inactivated it during viral infection ([@B247]). Infection by HCV, vesicular stomatitis virus (VSV), or Sendai virus, or direct exposure of cells to type 1 and 3 interferons increases expression of the cellular long non-coding RNA (lncRNA), namely lncATV, which similarly inhibits RIG-I function by directly interacting with it in order to promote virus replication ([@B248]). In addition to the greatly increased implications of RIG-I and MDA5 modulation, these findings also have significant implications in characterizing new biomarkers of disease, as increased serum selenoprotein level has been found to significantly associate with treatment failure of anti-viral drugs in HCV patients, and can possibly explain the increased prevalence of type 2 diabetes in HCV patients ([@B247]).

Cellular RNA has also been found to activate RLR signaling during viral infection. Vault RNAs, which are transcribed from four genes and are normally found in large ribonucleoprotein complexes in cytoplasmic "vaults," are significantly enriched for binding to RIG-I during infection with KSHV ([@B29]). This may be due partly to viral infection-induced reduction in the level of cellular triphosphatase DUSP11, which dephosphorylates the 5′ppp group on the vault RNAs, as they could only be immunogenic (in the absence of viral infection) by the addition of the 5′ppp group. RIG-I and MDA5 have also been found to be activated by RNA microparticles produced *in situ* by rolling circle transcription, generating tandem repeat RNA strands ([@B249]). Retrotransposons may also be able to activate both RIG-I and MDA5, as both can be activated by LINE1 RNA independently of DNA sensing mechanisms and retrotransposition ([@B250]).

Viral infections can also induce recognition of host RNAs. Herpes Simplex Virus 1 (HSV1) infection, for example, has been shown to induce translocation of the host pseudogene *RNA5SP141* ribosomal RNA into the cytosol to bind to RIG-I. Knockdown of *RNA5SP141* decreased cytokine signaling during infection with HSV and EBV as well as influenza A virus (IAV) ([@B251]). RIG-I has also been found to be activated by hairpin RNA structures generated by cleavage of RNA by RNase L, which has been demonstrated to occur during HCV infection ([@B179]) as well as from mitochondrial dsRNA produced in p53 deficient mice ([@B180]). The mitochondria, in particular, may be an important source of immunostimulatory host dsRNA. Viral infections are well-known to cause mitochondrial damage ([@B252]). Knockdown and hepatocyte-specific conditional KO of mitochondrial RNA degrading enzymes resulted in the increase of cytoplasmic mitochondrial dsRNA which was able to activate MDA5 ([@B253]). Additionally, extracellular vesicles (EV) secreted by apoptotic endothelial cells were found to contain long interspersed nuclear element (LINE) and short interspersed nuclear element (SINE) RNAs that are products of RNA polymerase III and were able to activate RIG-I signaling ([@B254]). Collectively, these findings demonstrate the many unique ways by which cellular RNAs can modulate RIG-I and MDA5 functions as well as the potential implications of RIG-I activation by pharmaceuticals as an anti-viral or generalized immunotherapy, though much caution and studies would still be needed to determine the appropriate levels of RIG-I and MDA5 activation.

Viral Modulations of RIG-I and MDA5 Functions {#s10}
=============================================

Given that RIG-I and MDA5 are critical for activating expression of IFN1 during viral infection, there is much interest in studying the interactions of these cellular proteins with viral factors (RNAs or proteins), as the ability to modulate interferon expression is a major evolutionary driving force in viral evolution ([@B255], [@B256]). There are many mechanisms viruses have evolved to evade RIG-I and MDA5 signaling, which have been discussed at length elsewhere ([@B257], [@B258]). Such mechanisms are of particular importance to segmented RNA viruses, providing potentially more dsRNAs for RIG-I and MDA5 activation ([@B259]). IAV and the other orthomyxoviruses are unique in that they replicate in the nucleus of the cells ([@B260]), preventing the viral RNA from being detected by the PRRs. However, recent preliminary evidence seems to suggest that RIG-I may also endogenously be present in the nucleus and performs similar viral RNA binding and activation of the IFN1 pathway ([@B261]), yet this finding has yet to be replicated by other laboratories.

There is also increasing evidence to suggest that RNA processing is another mechanism of immune modulation. Certain bunyaviruses can cleave the 5′ tri-phosphate group from their genomic RNA ([@B262]) in order to avoid immune detection. RIG-I has also been found to be subjected to negative modulation by RNAi during IAV infection ([@B263]). On the contrary, nucleoproteins from the Sendai virus ([@B264]) regulate the number of DI particles being produced, and IAV nucleoproteins also regulate the production of abortive replication RNA ([@B208]), mini viral RNAs ([@B265]) and DVG RNA ([@B208]), all of which are immunostimulatory. The Semliki Forest virus (SFV) polymerase has even been found to convert host RNA into 5′-ppp dsRNA to induce IFN1 expression ([@B266]). This raises an intriguing possibility that induction of IFN1 may actually benefit some viruses under certain circumstances despite IFN1 signaling negatively regulating viral replication.

The viral RNA levels and localization throughout the viral life cycle might also play an important role in immune evasion ([@B267]). Control of viral RNA levels by viral exoribonucleases in particular illustrates the complicated balance between viral production and immune evasion for optimal viral propagation, as has found to be the case for arenaviral nucleoproteins (NPs) ([@B268], [@B269]) and non-structural proteins found in coronaviruses ([@B270], [@B271]). Finally, viral infection has the capability to disrupt processes of the cell\'s basic functions, such as transcription and translation, thereby affecting viral replication and immune signaling in complicated ways ([@B258]).

One of the most significant ways viruses modulate RIG-I and MDA5 signaling is through their viral proteins ([@B272]) ([Figure 6](#F6){ref-type="fig"}). The respiratory syncytial virus (RSV) non-structural protein (NS2) protein and the Z matrix proteins of pathogenic arenaviruses interact with the RIG-I CARD domains to block its interaction with MAVS ([@B273], [@B274]). The HSV1 deamidase UL37 specifically targets RIG-I through its helicase domain, abrogating its ability to bind to RNA ([@B275]). The IAV polymerase components also interact directly with RIG-I ([@B276]), though their biological significance has yet to be determined as they don\'t significantly affect IFN1 production. On the other hand, RNA binding appears to be an important bridge between the interaction of RIG-I with other viral proteins, as the nucleoproteins (NPs) of IAV ([@B276]) and arenaviruses ([@B277], [@B278]) both interact with RIG-I through viral RNA. The NS1 protein of rotaviruses targets RIG-I for degradation that is independent of proteasomes ([@B279]). The V protein of paramyxoviruses inhibits MDA5 ([@B40]) by targeting a unique feature of the ATP binding pocket in MDA5 ([@B280]) and by inhibiting MDA5 CARD dephosphorylation ([@B93]), but can also inhibit RIG-I by interacting with the CARD domain to prevent its ubiquitination by TRIM25 ([@B281]). Finally, the US11 protein of HSV1 ([@B282]) and the arenaviral Z matrix proteins ([@B274]) directly interact with and inhibit RIG-I and MDA5 in a similar fashion. There are also many other viral proteins that can regulate proteins in the RIG-I and MDA5 pathways, which have been discussed in detail elsewhere ([@B44], [@B53], [@B59], [@B96], [@B257], [@B283]).

![RIG-I/MDA5 interactions with host and cellular proteins. Host proteins (shown in purple) and viral proteins (shown in orange) that modulate RIG-I and MDA5 signaling are shown. Figure created using BioRender software.](fimmu-10-01586-g0006){#F6}

Modulations of RIG-I and MDA5 Functions by Their Post-translational Modifications and/or by Other Viral or Cellular Proteins {#s11}
============================================================================================================================

It is important to consider the different regulatory mechanisms of RIG-I and MDA5 when considering their different functionalities ([Figures 4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}). One of the key differences between these proteins is in their post-translation modifications ([@B96]). Ubiquitination of RIG-I is necessary for its activation ([@B118]) and is a point of negative regulation by host proteins ([@B117], [@B284], [@B285]), viral proteins ([@B281], [@B286], [@B287]) and ubiquitin mimics ([@B288]) as well as positively regulated by influenza B NS1 protein ([@B289]) and another ubiquitin mimic ([@B290]). On the contrary, MDA5 is more well-known to be negatively regulated by ubiquitination ([@B291]), with positive regulation by K63 ubiquitination being more controversial. While the deubiquitinase USP3 inhibits MDA5 as well as RIG-I, it is thought that this may be due to USP3 directly binding the MDA5 CARD domain to prevent RNA filamentation ([@B284]). This raises the question of how RIG-I can maintain its stability outside of the proteasome, as ubiquitination at other lysine residues in RIG-I besides K172 induces proteasomal degradation ([@B291]--[@B293]). This proteasomal degradation may be mediated by a p62 autophagic complex that associates with LRRC25/ISG15 ([@B294]) and SQSTM1 ([@B295]) and also mediates mitophagy and downregulation of MAVS signaling during measles virus infection ([@B296]).

One key observation is that, while both RIG-I and MDA5 are cleaved during picornavirus infection, this cleavage is mediated by the viral proteinase 3C^pro^ ([@B297]) and is independent of the proteasome ([@B298]) for RIG-I, whereas it is mediated by cellular caspases and the proteasome for MDA5 ([@B299]). MDA5 is also cleaved by caspases during apoptosis ([@B4]), though it hasn\'t been shown whether this is mediated by MDA5\'s ubiquitination sites. The ubiquitin linkage site may be a determinate of function, as the ubiquitin ligases RNF122 ([@B300]) and STUB1 ([@B293], [@B301]) have been shown to negatively regulate RIG-I catalyzed K48-linked ubiquitination as opposed to the known K63-linked ubiquitination at the K172, K849 and K851 activating sites, and RNF125 has also been proposed to K48 ubiquitinate RIG-I ([@B291]) (though it hasn\'t been shown directly) ([@B59]). TRIM40 has also been shown to negatively regulate RIG-I and MDA5 by K27 and K48 ubiquitination ([@B123]).

Substantiating the possibility that K63 ubiquitination on RIG-I may be functionally distinct from its other ubiquitination sites by protecting it from degradation is the finding that the NS1 protein of West Nile virus (WNV) targets both RIG-I and MDA5 for degradation by proteasomes. Additionally, NS1 inhibited K63 ubiquitination of RIG-I, but MDA5 was not found to be K63 ubiquitinated ([@B126]). Heat shock protein 90-alpha (HSP90) has been found to protect RIG-I from proteasomal degradation, but it is unknown which type of ubiquitination that is inhibited by HSP90 ([@B302]). Taken together, the experimental evidence suggests that RIG-I may be protected from proteasome degradation despite its activating ubiquitin moieties ([@B52]). This warrants further studies for mechanistic elucidation.

RIG-I and MDA5 additionally interact with different cellular co-factors, contributing to their differential regulations of function. RIG-I is well-known for being potentiated by proteins that also bind dsRNA, such as (PACT) ([@B303], [@B304]), which was first discovered as a protein activator of PKR, the serine/threonine-protein kinase 1 (TBK1) ([@B305]--[@B309]) and the oligoadenylate synthetase L (OASL) ([@B310]). PACT in particular has some functional similarities to RIG-I, as they each contain three distinct RNA binding domains ([@B311]) and interact with many of the same cellular co-factors, such as PKR ([@B312]) and Dicer ([@B312], [@B313]). Because of the important role of PACT in augmenting RIG-I function, it is a prime target for inhibition of RIG-I signaling by several viral proteins from diverse families of viruses ([@B314]--[@B316]), the molecular mechanisms of PACT inhibition by these viral proteins can vary and still need to be characterized in detail in future studies. Similarly, the host ribonucleoprotein RAVER1 can increase affinity of MDA5 for dsRNA ([@B317]), and the zinc-finger protein ZCCHC3 has recently been found do so for both RIG-I and MDA5 ([@B125]) in similar mechanisms to the other known RNA-binding proteins. On the contrary, the human hemoglobin subunit beta (HB) has recently been suggested to decrease MDA5 signaling by competing for long dsRNA, while HB can enhance RIG-I signaling by increasing K63 ubiquitination on RIG-I ([@B318]).

Several host factors interacting with RIG-I and MDA5 do so by yet undescribed mechanisms. PKR \[which is also activated by PACT ([@B319], [@B320]) and is sequestered by the cellular helicase DHX36 protein to form stress granules ([@B321], [@B322]) along with RIG-I ([@B323], [@B324]) and TRIM25 ([@B324])\] appears to have a novel and yet uncharacterized function in enhancing MDA5-dependent MAVS signaling that is dependent on the kinase activity of PKR ([@B325]). Additionally, the porcine Interferon-Inducible Oligoadenylate Synthetase-like protein (pOASL) has also been found to interact with and inhibit MDA5 by an unknown mechanism ([@B326]).

The RIG-I CARD domain interacts with MAVS to induce interferon signaling, so proteins that disrupt this interaction \[as it has been proposed for the Atg5 and Atg12 autophagy proteins ([@B59])\] can specifically inhibit RIG-I signaling. However, other cellular proteins, such as the complement protein gC1qR ([@B327]) and TARBP2 ([@B328]) that interact directly with MAVS, inhibit both RIG-I and MDA5. Lactate and hexokinase have also recently been found to inhibit RIG-I and MDA5 by interacting with MAVS, which may be significant in explaining the interplay between metabolism and immune signaling as glycolysis was found to be greatly decreased upon RLR signaling ([@B329]). Likewise, cellular proteins, such as NLRC5 ([@B330]) that interacts with the RIG-I and MDA5 CARD domains have been shown to block interaction of both RIG-I and MDA5 with MAVS. Contrarily, DHX15 has been identified as a RIG-I cofactor that interacts with the RIG-I CARD domains and with PAMP (dsRNA), thereby increasing RIG-I ATPase activity ([@B331]). Additionally, ADP-ribosylation factor proteins can block RIG-I and MDA5 from interacting with PAMPs and thereby inhibit their activation ([@B332], [@B333]). Lastly, the green tea molecule EGCG has also been shown to inhibit the ATPase function of RIG-I ([@B334]). The similarities and differences between RIG-I and MDA5 modulations and signaling are complex and will need to be elucidated further in future studies.

Evolution and Speciation of RIG-I/MDA5 and RIG-I/MDA5-like Proteins {#s12}
===================================================================

Despite their structural and mechanistic differences, it is important to emphasize that existing phylogenetic analysis indicates that RIG-I and MDA5 come from a common origin that is also shared among several other protein families ([Figure 7](#F7){ref-type="fig"}). The linkage of the helicase and DExD/H box protein appear to be ancient, as orthologs of these proteins are found in the Archaea kingdom ([@B335], [@B336]). MDA5 orthologs are found in most vertebrates ([@B184]), while RIG-I orthologs are only found in mammals, ducks, geese and some selected fish and reptiles ([@B184], [@B337]--[@B343]) ([Figures 2](#F2){ref-type="fig"}, [7](#F7){ref-type="fig"}).

![Evolutionary timeline of RIG-I, MDA5, and other related DExD/H-box helicases. The evolutionary tract of RIG-I, MDA5, and related DExD/H-box helicases are shown as a phylogenetic tree, along with their lowest level of biological taxonomy that these proteins are found in present day. In short, the precursor of the MDA5 helicase-CTD likely originated from a common ancestor with the precursor for LGP2, which was then duplicated to create the helicase-CTD precursor of RIG-I in the common ancestor of vertebrates. CARD2 was then grafted onto the helicase-CTD protein, and this protein was duplicated to create the CARD2-helicase-CTD precursor of MDA5. Finally, CARD1 was grafted onto these proteins in separate events, forming the modern-day RIG-I and MDA5.](fimmu-10-01586-g0007){#F7}

It is therefore likely that MDA5 evolved first, perhaps from a common ancestor with the closely related LGP2 helicase family ([@B184]), which is structural similar to RIG-I and MDA5 but lacks the CARD domains at its N terminus ([@B185]). LGP2 orthologs are also only found in vertebrates while the next closest related family of proteins (Dicer) are more ancient proteins. It has therefore been proposed that the RIG-I helicase-DExD/H complex may have been duplicated from MDA5 in the common ancestor of vertebrates ([@B184]). The association of the two CARD domains appears to have followed, as individual CARD domains are found in a variety of vertebrates that also encode caspases ([@B344], [@B345]), but only RIG-I, MDA5, and certain members of the Nacht family of NTPases ([@B346]) have two CARD domains. Phylogenetic analysis has shown that the helicase-DExD/H and CARD2 have strong co-evolution history ([@B347], [@B348]), while CARD1 has evolved more independently ([@B184]). CARD2 appears to have been grafted onto the RIG-I helicase-DExD/H complex first, with the CARD2-MDA5 being duplicated from this event. Finally, CARD1 was grafted onto the CARD2-helicase-DExD/H complex in separate events for RIG-I and MDA5 ([@B184]). In mammals, positive selection can be seen in the flexible hinge region connecting the CARD domains to the helicase in RIG-I and MDA5. RIG-I contains an additional site of positive selection within the Hel1 structural motif (N421), while most of the unique positive selection sites for MDA5 are in regions specific to it, including a 29 amino acid insertion in Hel2 ([@B349]).

While RIG-I and MDA5 may both originate from common ancestors of vertebrates, there is increasing evidence to suggest that proteins with similar functions may have evolved separately in other species from ancient helicase-DExD/H proteins, implicating RNA-mediated defense responses as a potentially universal biological function. A RIG-I homolog has recently been found in a planarian that is able to activate downstream inflammatory genes in the absence of the traditional CARD domains ([@B350]), and a similar homolog in *Caenorhabditis elegans* has been proposed to mediate anti-viral RNAi by complexing with Dicer and catalyzing their translocation on the viral genome ([@B351]). Additionally, insects have been found to primarily respond to RNA viruses by RNAi mediated by Dicer proteins ([@B352]). Dicer may potentially mediate dsRNA-activated anti-viral signaling pathways that is independent of RNAi pathways, as has been found to be the case for the expanded CAG-repeat dsRNA ([@B353]). Pattern recognition receptors (PRRs) that respond to viral RNA have not yet been found outside of the animal kingdom, as RLR-like proteins in prokaryotes do not have CARD domains and the PRRs in plants found so far are surface-receptor kinases that respond to external molecular elements of bacteria ([@B354]) \[similar to the mammalian toll-like receptors (TLRs)\]. However, RNA silencing has been demonstrated to be an important anti-viral strategy in plants ([@B354], [@B355]) and certain *Arabidopsis* mutants appear to be more susceptible to infection by RNA viruses ([@B356]).

RIG-I ([@B357]) and MDA5 ([@B357], [@B358]) are known to influence antiviral signaling in zebrafish (*Danio rerio*) and other fish species ([@B357], [@B359]--[@B361]) through the canonical MAVS signaling pathway. Fish RIG-I like receptors (RLRs) have been shown to be regulated by the expression of alternate splicing isoforms ([@B358], [@B362]), which have also been found to occur with a dominant-negative splice variant of the human RIG-I ([@B363]). RIG-I and MDA5 have also been found to participate in anti-viral signaling in ducks ([@B364]--[@B367]) and geese ([@B340], [@B368], [@B369]), and MDA5 alone in chickens ([@B370]--[@B372]) and other birds ([@B373]). The observation across species of RLR\'s performing compensatory mechanisms when a function or a pathway protein is absent is reiterated in birds, as MDA5 has been found to sense short and long dsRNA in chickens ([@B372]) and in the Chinese shrew ([@B374]), both of which lack RIG-I. Additionally, TRIM25 activates RIG-I in ducks ([@B364]) and in the Chinese goose ([@B375]) in the absence of the K172 activating ubiquitin binding site that is conserved in primates and some rodents ([@B364]). Finally, the rainbow trout (*Oncorhynchus mykiss*) has been found to express a LGP2 variant in addition to the canonical LGP2 that contains an incomplete C-terminal domain of RIG-I ([@B376]). The differential presence of PRRs may also influence viral evolution. A mutation in the IAV polymerase subunit PB2 found in avian-adapted H1N1 strains decreases the inhibition of human RIG-I function by IAV nucleoproteins, which may indicate a differential selective pressure for viruses that propagate in species that don\'t contain RIG-I ([@B377]). The evolutionary pattern and compensatory mechanisms of RLRs across species implicate them as critical for anti-viral function, and that evolutionary forces drive the available pathway proteins to meet these functional needs. Future studies need to be done to further differentiate RLR function among the different species, as this will provide critical information concerning the various methods of disease control by targeting the pathogen by these important host proteins.

There is also increasing evidence for other RNA-sensing DExD/H helicases serving important roles in anti-pathogen immune sensing, which have recently been reviewed elsewhere ([@B187]). Some RNA helicase (DDX) proteins appear to serve as complex proteins upon interacting with viral RNA. DDX3 is a well-known example, being suspected of being a transcription factor for IFN-β ([@B378]), associating with spliceosomes and the stress-induced p-bodies to influence mRNA splicing and decay, respectively ([@B322], [@B378]), and interacting with the MAVS complex during viral infection conditions ([@B378], [@B379]). In particular, DDX3 associating with MAVS has been found to be important for anti-viral control against several viruses ([@B378]--[@B380]), and since the two DDX3 homologs are found on the X and Y chromosomes, they may contribute to immunological differences between genders ([@B381]). This is a repeated theme, as DHX9 ([@B382]), DHX15 ([@B383]), and a complex consisting of DDX1/DDX21/DHX36 ([@B384]) have also been found to associate with the MAVS complex to enhance IFN1 signaling, while DHX33 interacts with MAVS independently of viral infection ([@B385]). DDX proteins can also activate other proteins in the IRF pathway. Multiple DDX proteins can interact with IKKε, with DDX3 being phosphorylated by IKKε to induce IRF3 interaction with the TBK1-IKKε complex ([@B378]), and DDX19 blocking this interaction to inhibit IFN1 signaling ([@B386]). Similar control mechanisms have been demonstrated for DDX3 interacting with viral proteins. For example, DDX3 has recently been found to associate with arenaviral NPs to increase viral RNA synthesis and IFN1 expression ([@B387]). Additionally, the NP of the 1918 H1N1 IAV pandemic strain has been shown to target DDX3 for degradation as a potential mechanism of virulence ([@B388]). DHX15 ([@B389]) and DHX33 have also been found to activate NFκB and MAPK signaling pathways. Finally, DDX60 has been shown to act as a cofactor for RIG-I ([@B390], [@B391]) and DHX29 for MDA5 ([@B392]). Taken altogether, these cellular proteins have likely evolved to regulate RIG-I and MDA5 signaling from their common DExD/H helicase predecessors.

Summary and Future Outlooks {#s13}
===========================

As our capacity to study the molecular mechanisms and to purposefully modulate immune responses increases in specificity, so will our needs to characterize the differences between related immune signaling proteins. The concept of personalized medicine derives from the idea that we can therapeutically intervene in a situation that is designed around the individual\'s unique characteristics. While this is an achievable realm of medicine in the future, an immediate step is to determine the functions of some critical proteins, such as the RIG-I and MDA5 of the innate immune arm. Examining their structural and functional similarities and differences at multiple levels will allow for a deeper level of appreciation of these proteins, which may be exploited therapeutically to differentially modulate RIG-I and MDA5 signalings by different RNA ligands ([@B43], [@B191], [@B393], [@B394]) or other pharmaceutical compounds ([@B395]) toward the goal of achieving personalized medicine.
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